The Role of Education in Adjusting to Changes in Clinical Practice for Gastric or Gastroesophageal Junction Adenocarcinomas

Authors: Tariqa Ackbarali, PhD¹; Yelena Y. Janjigian, MD²; Eric Van Cutsem, MD, PhD³ Affiliations: ¹PlatformQ Health, Needham, MA; ²Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; ³University of Leuven, Leuven, Belgium

This activity is supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc.; and Merck.












INTRODUCTION


BACKGROUND: Gastric or gastroesophageal junction (GEJ) adenocarcinomas are difficult to treat and associated with poor prognosis, specifically in advanced disease. Recently approved and investigational immune checkpoint inhibitors (ICIs) and HER2-directed antibody-drug conjugates (ADCs) are changing the treatment landscapes for



gastric cancer and GEJ cancer, allowing clinicians to manage difficult-to-treat patients. However, these advances also created knowledge and practice gaps that pose many challenges. Education was needed to assess current practices and close these gaps.

METHODOLOGY

Educational Program and Evaluation Details




Interventions

A 4-part CME-certified series launched online in December 2021 and remains on-demand through December 2022 at OMedLive.com.

Gastric or Gastroesophageal Junction Adenocarcinoma Adverse Event Treatment of Current Care fo

Expanding Treatment Options with ADCs in HER2-Positive



Distribution partner: American Gastroenterological Association (AGA)

Education: PlatformQ Health and Postgraduate Institute for Medicine (PIM)

Questions asked before, immediately post, and 2 months after the activity. Chi Square tests were used for statistical analysis.

Changes in knowledge and competence, reported behavior, engagement, and identification of continuing gaps.

Faculty



Yelena Y. Janjigian, MD
Associate Professor and Chief of



Eric Van Cutsem, MD, PhD **Professor of Medicine Head Digestive Oncology** University of Leuven, Belgium

RESULTS

Learner Demographics


Learner Engagement



2,004



MD/NP/PA





awarded



slide downloads




"I have closer collaboration within the treatment team."


"I am more comfortable with HER2 testing and differences in gastric versus breast."

"I have initiated new clinical research studies."


"I emphasize to my patients the importance of molecular testing for current treatment of gastric and GEJ carcinoma."


Changes in Knowledge/Competence






weekly average of patients seen with HER2+ gastric or GEJ adenocarcinoma







Knowledge of average time of onset of adverse events




Knowledge of intratumoral HER2 heterogeneity in



Competence choosing first-line therapy for an unresectable, metastatic gastric adenocarcinoma patient



Competence choosing first-line therapy for a stage IV gastric adenocarcinoma patient



Provider Insights

Preferred approach to managing interstitial lung disease (ILD) for a patient being treated with a HER2 antibody drug conjugate:

n = 2,004 pretest, n = 1,267 posttest; **P*<0.05


Knowledge of adverse

events leading to

dose reduction



Perception of novel HER2-targeted agents with greatest potential for gastric or GEJ cancers:



Repeat testing of HER2 expression following progression on a trastuzumab-containing regimen:



CONCLUSION

This serialized education was effective in improving knowledge and competence across four major themes of practice within gastric and GEJ cancer management. Provider insights revealed practice shifts following participation and practice impact assessments demonstrated the rapid application of real-time digital education.

This presentation is the intellectual property of the author/presenter. Contact them at tackbarali@platformq.com for permission to reprint and/or distribute.